Augmenting Cognitive Function in the Elderly with Mild Cognitive Impairment Using Probiotic Lacticaseibacillus rhamnosus CBT-LR5: A 12-Week Randomized, Double-Blind, Parallel-Group Non-Comparative Study

被引:0
|
作者
Jung, Su-Jin [1 ,2 ]
Cho, Kyohee [3 ]
Jung, Eun-Soo [1 ]
Son, Dooheon [3 ]
Byun, Jong-Seon [3 ]
Kim, Song-In [3 ]
Chae, Soo-Wan [1 ,2 ]
Yang, Jong-Chul [1 ,2 ,4 ]
Lee, Seung-Ok [1 ,2 ,5 ,6 ]
Lim, Sanghyun [3 ]
机构
[1] Jeonbuk Natl Univ Hosp, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[3] Cell Biotech Co Ltd, R&D Ctr, Gimpo Si 10003, South Korea
[4] Jeonbuk Natl Univ, Med Sch, Dept Psychiat, Jeonju 54896, South Korea
[5] Jeonbuk Natl Univ Hosp, Dept Gastroenterol & Hepatol, Jeonju 54896, South Korea
[6] Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju 54896, South Korea
关键词
mild cognitive impairment (MCI); <italic>Lacticaseibacillus rhamnosus</italic> CBT-LR5; skim milk; probiotics; cognitive function; clinical trial; GUT-BRAIN AXIS; BIOACTIVE PEPTIDES; FERMENTED MILK; MICROBIOTA; MEMORY; EDUCATION; DEMENTIA;
D O I
10.3390/nu17040691
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Probiotics have been shown to enhance cognitive function in individuals with mild cognitive impairment (MCI), but their efficacy varies, depending on the strain and dosage. Objectives: Clinical investigations are crucial to confirm their safety, efficacy, and mechanism of action. This study was designed to assess the effective dosage, safety, and efficacy of MH-Pro, a test product containing Lacticaseibacillus rhamnosus CBT-LR5 (LR5) and skim milk (non-fat dry milk), in improving cognitive function and related physiological changes in older adults suspected of MCI over 12 weeks. Methods: In total, 20 participants (mean age: 68.9 years) were randomly assigned in a 1:1 ratio to either a low-dose group (1 x 1010 CFU LR5 with 1622 mg) or a high-dose group (1 x 1010 CFU LR5 with 4055 mg skim milk) in a double-blind, parallel-group clinical trial. Results: After 12 weeks, the low-dose group showed significant improvements in the MOCA-K subdomains, specifically in naming (p = 0.01) and delayed recall (p = 0.003). Additionally, levels of amyloid-beta 1 40/42 in the blood significantly decreased (p = 0.03) following supplementation in the low-dose group. The high-dose group exhibited significant improvement in orientation (p = 0.05). Moreover, overall cognitive enhancement was observed in the low-dose group (p = 0.003), while the high-dose group showed a trend toward improvement (p = 0.06). Fecal analysis revealed significant changes in bacterial composition, with an increase in Lacticaseibacillus after 12 weeks of MH-Pro consumption. Together, these findings provide foundational evidence suggesting that MH-Pro supplementation may serve as a potential intervention for enhancing cognitive function through gut-brain axis pathways in the elderly population. However, given the small sample size and the predominance of female participants, the impact of the outcome may be limited. Further large-scale studies are necessary to validate these preliminary results. Conclusions: This study provides foundational evidence to recognize the use of LR5 and skim milk to prepare a probiotic supplement that enhances cognitive function in the aging population.
引用
收藏
页数:19
相关论文
共 38 条
  • [1] A randomized, double-blind, placebo-controlled, parallel-group 12-week pilot phase II trial of SaiLuoTong (SLT) for cognitive function in older adults with mild cognitive impairment
    Steiner-Lim, Genevieve Z.
    Bensoussan, Alan
    Andrews-Marney, Elana R.
    Al-Dabbas, Mahmoud A.
    Cave, Adele E.
    Chiu, Christine L.
    Christofides, Katerina
    De Blasio, Frances M.
    Dewsbury, Lauren S.
    Fagan, Naomi L.
    Fogarty, Jack S.
    Hattom, Lena C.
    Hohenberg, Mark I.
    Jafar, Deyyan
    Karamacoska, Diana
    Lim, Chai K.
    Liu, Jianxun
    Metri, Najwa-Joelle
    Oxenham, D. Vincent
    Ratajec, Holly
    Roy, Nikita
    Shipton, Danielle G.
    Varjabedian, David
    Chang, Dennis H.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2023, 9 (04)
  • [2] Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
    Budimirovic, Dejan B.
    Dominick, Kelli C.
    Gabis, Lidia, V
    Adams, Maxwell
    Adera, Mathews
    Huang, Linda
    Ventola, Pamela
    Tartaglia, Nicole R.
    Berry-Kravis, Elizabeth
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study
    Schaefer, Franz
    Litwin, Mieczyslaw
    Zachwieja, Jacek
    Zurowska, Aleksandra
    Turi, Sandor
    Grosso, Amie
    Pezous, Nicole
    Kadwa, Mahomed
    JOURNAL OF HYPERTENSION, 2011, 29 (12) : 2484 - 2490
  • [4] EFFICACY OF PROBIOTICS ON THE COGNITIVE FUNCTION, SLEEP EFFICIENCY, AND ANTIOXIDATIVE BIOMARKERS IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA: A 12-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP CLINICAL TRIAL
    Sun, Y.
    Kuo, Y. -W.
    Tsai, S. -Y.
    Lin, J. -H.
    Hsu, Y. -C.
    Chen, J. -F.
    Hsia, K. -C.
    Ho, H. -H.
    Liu, H. -H.
    Kua, H. -C.
    SLEEP MEDICINE, 2024, 115 : 234 - 234
  • [5] Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment
    Steiner, Genevieve Z.
    Bensoussan, Alan
    Liu, Jianxun
    Hohenberg, Mark I.
    Chang, Dennis H.
    TRIALS, 2018, 19
  • [6] Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment
    Genevieve Z. Steiner
    Alan Bensoussan
    Jianxun Liu
    Mark I. Hohenberg
    Dennis H. Chang
    Trials, 19
  • [7] Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study
    Inoue, Yuichi
    Hirata, Koichi
    Uchimura, Naohisa
    Kuroda, Kenji
    Hattori, Nobutaka
    Takeuchi, Masahiro
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (01) : 13 - 21
  • [8] CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study
    Ross, Joel
    Sharma, Sanjiv
    Winston, Jaron
    Nunez, Margarita
    Bottini, Gabriella
    Franceschi, Massimo
    Scarpini, Elio
    Frigerio, Enrico
    Fiorentini, Francesco
    Fernandez, Mercedes
    Sivilia, Sandra
    Giardino, Luciana
    Calza, Laura
    Norris, Dottie
    Cicirello, Helen
    Casula, Daniela
    Imbimbo, Bruno P.
    CURRENT ALZHEIMER RESEARCH, 2013, 10 (07) : 742 - 753
  • [9] Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with HypertensionThe TRINITY Randomized, Double-Blind, 12-Week, Parallel-Group Study
    Steven G. Chrysant
    Thomas Littlejohn
    Joseph L. Izzo
    Dean J. Kereiakes
    Suzanne Oparil
    Michael Melino
    James Lee
    Victor Fernandez
    Reinilde Heyrman
    American Journal of Cardiovascular Drugs, 2012, 12 (4) : 233 - 243
  • [10] Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension The TRINITY Randomized, Double-Blind, 12-Week, Parallel-Group Study
    Chrysant, Steven G.
    Littlejohn, Thomas, III
    Izzo, Joseph L., Jr.
    Kereiakes, Dean J.
    Oparil, Suzanne
    Melino, Michael
    Lee, James
    Fernandez, Victor
    Heyrman, Reinilde
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2012, 12 (04) : 233 - 243